Mar 07, 2014 at 22:07 | Source: PTI
Giving its nod, CCI said "there would be no change in the ultimate control as a result of the proposed combination".
Mar 05, 2014 at 09:14 | Source: Moneycontrol.com
According to Way2Wealth.com, Nifty will face stiff resistance around 6320-6350 levels and from those levels profit booking is expected.
Mar 04, 2014 at 15:55 | Source: CNBC-TV18
SP Tulsian of sptulsian.com is of the view that Glenmark Pharma may test Rs 650 in next six months.
Mar 04, 2014 at 09:20 | Source: Moneycontrol.com
Bank of America Merrill Lynch says that 8-15 percent of sales come from Glenmark Pharma, Ranbaxy Labs and Dr Reddys Labs and 75 percent of exposure is towards Russia whereas the remaining exposure is towards Ukraine as well as other CIS countries. The impact could be higher due to the currency depreciation of the Russian ruble.
Mar 03, 2014 at 20:46 | Source: CNBC-TV18
Ireland drug maker Actavis (Watson) has also been sued by Sanofi for its generic application along with Glenmark.
Mar 03, 2014 at 09:57 | Source: Moneycontrol.com
According to Way2Wealth.com, on lower side Nifty will find immediate support around 6250-6230 levels. On higher side call writing at 6300 will act as stiff resistance for indices in short term.
Feb 19, 2014 at 12:20 | Source: CNBC-TV18
According to Ajay Bodke, head-investment strategy & advisory at Prabhudas Lilladher, Dr Reddys Laboratories may test Rs 3023 in one year period.
Feb 10, 2014 at 10:54 | Source: Moneycontrol.com
According to Satish Gupta of astrostocktips.in, pharma stocks like Sun Pharmaceutical Industries, Glenmark Pharma, Cipla, Dr Reddys Laboratories, Wockhardt and Elder Pharmaceuticals will get astrological support.
Feb 07, 2014 at 13:26 | Source: CNBC-TV18
Deven Choksey, MD of KR Choksey Shares & Securities prefers Glenmark Pharma and Cipla within the pharma space.
Feb 03, 2014 at 14:29 | Source: Moneycontrol.com
Sushil Finance has recommended a hold rating on Glenmark Pharma with a target price of Rs 580, in its January 29, 2014. research report.